You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global Antifungal infection Therapeutics Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

Market Analysis and Insights: Global Antifungal infection Therapeutics Market
The research report studies the Antifungal infection Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Antifungal infection Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Antifungal infection Therapeutics Scope and Segment
The global Antifungal infection Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antifungal infection Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Polyenes
Echinocandins
Azoles
Allylamines
Other Drug types
by Application, this report covers the following segments
Powders
Pastes
Ointments
Drugs
Other Applications
Global Antifungal infection Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Antifungal infection Therapeutics key players in this market include:
Scynexis
Sanofi-Aventis
Pfizer
Novartis
Merck & Co
Kramer Laboratories
Johnson & Johnson
ID Sigma-Aldrich Corporation
Glenmark Pharmaceuticals
Glaxosmithkline
Enzon Pharmaceuticals
Bayer Healthcare
Astellas Pharma
Asperqillus
Alternaria
Abbott Laboratories
1 Market Overview of Antifungal infection Therapeutics
1.1 Antifungal infection Therapeutics Market Overview
1.1.1 Antifungal infection Therapeutics Product Scope
1.1.2 Antifungal infection Therapeutics Market Status and Outlook
1.2 Global Antifungal infection Therapeutics Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Antifungal infection Therapeutics Market Size by Region (2016-2027)
1.4 Global Antifungal infection Therapeutics Historic Market Size by Region (2016-2021)
1.5 Global Antifungal infection Therapeutics Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Antifungal infection Therapeutics Market Size (2016-2027)
1.6.1 North America Antifungal infection Therapeutics Market Size (2016-2027)
1.6.2 Europe Antifungal infection Therapeutics Market Size (2016-2027)
1.6.3 Asia-Pacific Antifungal infection Therapeutics Market Size (2016-2027)
1.6.4 Latin America Antifungal infection Therapeutics Market Size (2016-2027)
1.6.5 Middle East & Africa Antifungal infection Therapeutics Market Size (2016-2027)
2 Antifungal infection Therapeutics Market Overview by Type
2.1 Global Antifungal infection Therapeutics Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Antifungal infection Therapeutics Historic Market Size by Type (2016-2021)
2.3 Global Antifungal infection Therapeutics Forecasted Market Size by Type (2022-2027)
2.4 Polyenes
2.5 Echinocandins
2.6 Azoles
2.7 Allylamines
2.8 Other Drug types
3 Antifungal infection Therapeutics Market Overview by Application
3.1 Global Antifungal infection Therapeutics Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Antifungal infection Therapeutics Historic Market Size by Application (2016-2021)
3.3 Global Antifungal infection Therapeutics Forecasted Market Size by Application (2022-2027)
3.4 Powders
3.5 Pastes
3.6 Ointments
3.7 Drugs
3.8 Other Applications
4 Antifungal infection Therapeutics Competition Analysis by Players
4.1 Global Antifungal infection Therapeutics Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antifungal infection Therapeutics as of 2020)
4.3 Date of Key Players Enter into Antifungal infection Therapeutics Market
4.4 Global Top Players Antifungal infection Therapeutics Headquarters and Area Served
4.5 Key Players Antifungal infection Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Antifungal infection Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Scynexis
5.1.1 Scynexis Profile
5.1.2 Scynexis Main Business
5.1.3 Scynexis Antifungal infection Therapeutics Products, Services and Solutions
5.1.4 Scynexis Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.1.5 Scynexis Recent Developments
5.2 Sanofi-Aventis
5.2.1 Sanofi-Aventis Profile
5.2.2 Sanofi-Aventis Main Business
5.2.3 Sanofi-Aventis Antifungal infection Therapeutics Products, Services and Solutions
5.2.4 Sanofi-Aventis Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.2.5 Sanofi-Aventis Recent Developments
5.3 Pfizer
5.3.1 Pfizer Profile
5.3.2 Pfizer Main Business
5.3.3 Pfizer Antifungal infection Therapeutics Products, Services and Solutions
5.3.4 Pfizer Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Antifungal infection Therapeutics Products, Services and Solutions
5.4.4 Novartis Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.4.5 Novartis Recent Developments
5.5 Merck & Co
5.5.1 Merck & Co Profile
5.5.2 Merck & Co Main Business
5.5.3 Merck & Co Antifungal infection Therapeutics Products, Services and Solutions
5.5.4 Merck & Co Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.5.5 Merck & Co Recent Developments
5.6 Kramer Laboratories
5.6.1 Kramer Laboratories Profile
5.6.2 Kramer Laboratories Main Business
5.6.3 Kramer Laboratories Antifungal infection Therapeutics Products, Services and Solutions
5.6.4 Kramer Laboratories Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.6.5 Kramer Laboratories Recent Developments
5.7 Johnson & Johnson
5.7.1 Johnson & Johnson Profile
5.7.2 Johnson & Johnson Main Business
5.7.3 Johnson & Johnson Antifungal infection Therapeutics Products, Services and Solutions
5.7.4 Johnson & Johnson Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.7.5 Johnson & Johnson Recent Developments
5.8 ID Sigma-Aldrich Corporation
5.8.1 ID Sigma-Aldrich Corporation Profile
5.8.2 ID Sigma-Aldrich Corporation Main Business
5.8.3 ID Sigma-Aldrich Corporation Antifungal infection Therapeutics Products, Services and Solutions
5.8.4 ID Sigma-Aldrich Corporation Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.8.5 ID Sigma-Aldrich Corporation Recent Developments
5.9 Glenmark Pharmaceuticals
5.9.1 Glenmark Pharmaceuticals Profile
5.9.2 Glenmark Pharmaceuticals Main Business
5.9.3 Glenmark Pharmaceuticals Antifungal infection Therapeutics Products, Services and Solutions
5.9.4 Glenmark Pharmaceuticals Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.9.5 Glenmark Pharmaceuticals Recent Developments
5.10 Glaxosmithkline
5.10.1 Glaxosmithkline Profile
5.10.2 Glaxosmithkline Main Business
5.10.3 Glaxosmithkline Antifungal infection Therapeutics Products, Services and Solutions
5.10.4 Glaxosmithkline Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.10.5 Glaxosmithkline Recent Developments
5.11 Enzon Pharmaceuticals
5.11.1 Enzon Pharmaceuticals Profile
5.11.2 Enzon Pharmaceuticals Main Business
5.11.3 Enzon Pharmaceuticals Antifungal infection Therapeutics Products, Services and Solutions
5.11.4 Enzon Pharmaceuticals Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.11.5 Enzon Pharmaceuticals Recent Developments
5.12 Bayer Healthcare
5.12.1 Bayer Healthcare Profile
5.12.2 Bayer Healthcare Main Business
5.12.3 Bayer Healthcare Antifungal infection Therapeutics Products, Services and Solutions
5.12.4 Bayer Healthcare Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.12.5 Bayer Healthcare Recent Developments
5.13 Astellas Pharma
5.13.1 Astellas Pharma Profile
5.13.2 Astellas Pharma Main Business
5.13.3 Astellas Pharma Antifungal infection Therapeutics Products, Services and Solutions
5.13.4 Astellas Pharma Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.13.5 Astellas Pharma Recent Developments
5.14 Asperqillus
5.14.1 Asperqillus Profile
5.14.2 Asperqillus Main Business
5.14.3 Asperqillus Antifungal infection Therapeutics Products, Services and Solutions
5.14.4 Asperqillus Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.14.5 Asperqillus Recent Developments
5.15 Alternaria
5.15.1 Alternaria Profile
5.15.2 Alternaria Main Business
5.15.3 Alternaria Antifungal infection Therapeutics Products, Services and Solutions
5.15.4 Alternaria Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.15.5 Alternaria Recent Developments
5.16 Abbott Laboratories
5.16.1 Abbott Laboratories Profile
5.16.2 Abbott Laboratories Main Business
5.16.3 Abbott Laboratories Antifungal infection Therapeutics Products, Services and Solutions
5.16.4 Abbott Laboratories Antifungal infection Therapeutics Revenue (US$ Million) & (2016-2021)
5.16.5 Abbott Laboratories Recent Developments
6 North America
6.1 North America Antifungal infection Therapeutics Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Antifungal infection Therapeutics Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Antifungal infection Therapeutics Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Antifungal infection Therapeutics Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Antifungal infection Therapeutics Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Antifungal infection Therapeutics Market Dynamics
11.1 Antifungal infection Therapeutics Industry Trends
11.2 Antifungal infection Therapeutics Market Drivers
11.3 Antifungal infection Therapeutics Market Challenges
11.4 Antifungal infection Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • FORMAT: PDF
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 125